China claims that four GlaxoSmithKline executives are involved in a massive bribery scheme to boost drug sales including travel costs, meeting expenses, and sexual favors going back over five years. Glaxo, for its part, is taking a tough stance, touting its zero-tolerance policy and sending key executives to personally handle the situation.
In this video, health-care analyst David Williamson discusses what this development means for Glaxo, how the company can turn this crisis into an opportunity, and what investors really need to be focused on in the pharma's pipeline.
China is a major growth driver for Big Pharma, but did you know China is already the world's largest auto market -- and it's set to grow even bigger in coming years? A recent Motley Fool report, "2 Automakers to Buy for a Surging Chinese Market," names two global giants poised to reap big gains that could drive big rewards for investors. You can read this report right now for free -- just click here for instant access.
The article Sex, Drugs, and China Woes originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline. Follow David on Twitter: @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.